Ardigen's news feed
10.01.2025 Business
Share news in:

Ardigen joins the OASIS Consortium to advance multi-omics safety assessment

 

 

Ardigen has proudly joined the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium as a tech partner and collaborator. This partnership positions Ardigen alongside prominent industry leaders (such as Amazon Web Services, Axiom Bio, BioSpyder, EU-OPENSCREEN, Nomic Bio, Revvity, and Xellar Biosystems) along with many government and academic organizations in a collaborative effort to push the boundaries of multi-omics technologies for safety assessment.

Convened in July 2023 by the Health and Environmental Sciences Institute (HESI) in collaboration with the Broad Institute of Harvard and MIT, OASIS is a cutting-edge initiative supported by the Massachusetts Life Sciences Center (MLSC). The consortium brings together over 60 global experts from academia, industry, government, and NGOs, creating a unique multi-disciplinary ecosystem. With its focus on integrating Cell Painting, transcriptomics, and proteomics across various cell models, OASIS aims to develop innovative tools for assessing chemical safety, with hepatotoxicity as the initial test case.

Ardigen’s role as a tech partner involves contributing our expertise in data analysis, including our extensive experience and cutting-edge approaches to analyzing Cell Painting data. Ardigen will contribute to all consortium activities and the broader HESI Emerging Systems Toxicology for the Assessment of Risk (eSTAR) initiative. Additionally, Ardigen and other industry partners have the opportunity to add compounds of interest to the studies, enhancing the collaborative potential of the research.

The OASIS Consortium is tackling some of the biggest challenges in toxicology and drug development. Ardigen’s partnership with OASIS emphasizes its commitment to harnessing data-driven technologies for advancing drug discovery and development research and insights into human health. Together with its partners, Ardigen looks forward to contributing to the development of next-generation safety assessment methods and furthering innovation in toxicology.

10.12.2024
Your monthly AI in biotech digest - December
14.01.2025
Ardigen Joins the NVIDIA Inception Program to Accelerate AI Solutions in Life Sciences
Go up